For some patients with the most common type of lung cancer, known as lung adenocarcinoma, there's new hope. In a new study ...

A recently approved group of drugs - immune checkpoint inhibitors - can boost the body's ability to eliminate a tumor and ...

Former Alabama football player Bennett Whisenhunt beat cancer using lessons learned as a walk-on. How he survived Hodgkin's ...

Ahead of the upcoming American Society of Hematology annual meeting, a multicenter study published in the Journal of Clinical ...

The mycosis fungoides market is projected to experience consistent growth from 2025 to 2034, fueled by increasing disease awareness, earlier detection, and the availability of established treatment ...

The U.S. Centers for Medicare & Medicaid Services (CMS) rolled out the negotiated costs of the second batch of drugs subject to such bargaining. CMS said the adjusted maximum fair prices would have ...

Ding, X.F., Wang, J.L., Shi, A.Q., et al. (2021) Nasal Septal Schwannoma: A Case Report. Journal of China Clinic Medical Imaging, 32, 226-227. Mey, K.H., Buchwald, C., Daugaard, S. and Prause, J.U.

Bristol Myers Squibb BMY and Gilead Sciences, Inc. GILD are leading biotechnology companies with broad, diverse portfolios ...

Cancer’s deadliest talent is not rapid growth but the ability to sidestep the internal programs that should make damaged ...

Diffuse large B-cell lymphoma (DLBCL) is an aggressive blood cancer that kills most untreated patients within one year.

What's new in proton therapy? Read the latest news and views from Fred Hutch's proton therapy facility’s patients and ...

Lifileucel showed a 31.4% objective response rate and a median duration of response of 36.5 months in advanced melanoma patients. The median overall survival was 13.9 months, with adverse events ...